Subcutaneous abatacept in rheumatoid arthritis: A real-life experience

Smolen, 2018, Rheumatoid arthritis, Nat Rev Dis Prim, 4, 18001, 10.1038/nrdp.2018.1 Ramírez, 2015, Burden of illness of rheumatoid arthritis in Latin America: a regional perspective, Clin. Rheumatol., 34, S9, 10.1007/s10067-015-3012-0 Rein, 2017, Treatment with biologicals in rheumatoid arthritis: an overview, Rheumatol Ther, 4, 247, 10.1007/s40744-017-0073-3 Nam, 2014, Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann. Rheum. Dis., 73, 516, 10.1136/annrheumdis-2013-204577 Keystone, 2015, Subcutaneous abatacept in rheumatoid arthritis: current update, Expert Opin. Biol. Ther., 15, 1221, 10.1517/14712598.2015.1065248 Greene, 1996, Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions, J. Biol. Chem., 271, 26762, 10.1074/jbc.271.43.26762 Genovese, 2011, Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate, Arthritis Rheum., 63, 2854, 10.1002/art.30463 Nash, 2013, Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study, Arthritis Care Res., 65, 718, 10.1002/acr.21876 Kaine, 2012, Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study), Ann. Rheum. Dis., 71, 38, 10.1136/annrheumdis-2011-200344 Keystone, 2012, Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study, Ann. Rheum. Dis., 71, 857, 10.1136/annrheumdis-2011-200355 Sarmiento-Monroy, 2016, AB0354 Subcutaneous abatacept in patients with rheumatoid arthritis: a real-life experience, Ann Rheum Dis, 75, 1024 Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health n.d.;10:326–335. doi:10.1111/j.1524-4733.2007.00186.x. Nüßlein, 2014, Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study, BMC Muscoskelet. Disord., 15, 14, 10.1186/1471-2474-15-14 Murakami, 2018, Predictive factors for structural remission using abatacept: results from the ABROAD study, Mod. Rheumatol., 1 Takabayashi, 2018, Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data, Mod. Rheumatol., 1 Takahashi, 2015, Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks, J. Rheumatol., 42, 786, 10.3899/jrheum.141288 Nüßlein, 2015, Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study, BMC Muscoskelet. Disord., 16, 176, 10.1186/s12891-015-0636-9 Truchetet, 2016, Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry, Arthritis Res. Ther., 18, 72, 10.1186/s13075-016-0956-7 Finckh, 2015, The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries, RMD Open, 1, 10.1136/rmdopen-2014-000040 Dal Pra, 2012, Seguridad de abatacept en pacientes con artritis reumatoidea, Rev. Argent. Reumatol., 23, 30 Becerra Rojas, 2011, Costo efectividad de Abatacept en comparación con otras terapias biológicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el año 2010, Acta Med., 28, 200 van der Heijde, 2013, EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria, Ann. Rheum. Dis., 72, 479, 10.1136/annrheumdis-2012-202779 Pinheiro 2017, 201 Rojas-Villarraga, 2012, Introducing polyautoimmunity: secondary autoimmune diseases No longer exist, Autoimmune Dis., 254319, 1 Sarmiento-Monroy, 2017, Correlation between routine assessment of patient index data 3 (RAPID3) and disease activity score 28 (DAS28) in patients with rheumatoid arthritis treated with subcutaneous abatacept Pincus, 2008, RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories, J. Rheumatol., 35, 2136, 10.3899/jrheum.080182 Kremer, 2006, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial, Ann. Intern. Med., 144, 865, 10.7326/0003-4819-144-12-200606200-00003 Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, N. Engl. J. Med., 353, 1114, 10.1056/NEJMoa050524 Mola EM, Balsa A, Martínez Taboada V, Marenco JL, Navarro Sarabia F, Gómez-Reino J, et al. Practice guidelines for the use of subcutaneous abatacept. Reumatol Clin n.d.;10:218–226. doi:10.1016/j.reuma.2013.11.006. Desplats, 2017, Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study, Clin. Rheumatol., 36, 1395, 10.1007/s10067-017-3587-8 Conitec, 2016 Amano, 2015, Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders, Mod. Rheumatol., 25, 665, 10.3109/14397595.2015.1012786 Mueller, 2016, Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK), Arthritis Res. Ther., 18, 88, 10.1186/s13075-016-0985-2 Reggia, 2015, Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety, J. Rheumatol., 42, 193, 10.3899/jrheum.141042 Monti, 2015, Switching from intravenous to subcutaneous formulation of abatacept: different results in a series of 21 patients, J. Rheumatol., 42, 1993, 10.3899/jrheum.150230 D’Agostino, 2017, Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis, Clin. Rheumatol., 36, 2655, 10.1007/s10067-017-3788-1 Katkade, 2018, Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making, J. Multidiscip. Healthc., 11, 295, 10.2147/JMDH.S160029 Alten, 2014, Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment, Arthritis Rheum., 66, 1987, 10.1002/art.38687 Genovese, 2018, Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial, J. Rheumatol., 45, 1085, 10.3899/jrheum.170344 Sarmiento-Monroy, 2016, Factors associated with response to abatacept in rheumatoid arthritis: a systematic literature review Scarsi, 2010, Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response, J. Rheumatol., 37, 911, 10.3899/jrheum.091176 Scarsi, 2011, Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis, J. Rheumatol., 38, 2105, 10.3899/jrheum.110386 Gottenberg, 2012, Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the “Orencia and Rheumatoid Arthritis” registry, Ann. Rheum. Dis., 71, 1815, 10.1136/annrheumdis-2011-201109 Sokolove, 2016, Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial, Ann. Rheum. Dis., 75, 709, 10.1136/annrheumdis-2015-207942 Yazici, 2011, Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data, Clin. Exp. Rheumatol., 29, 494 Takahashi, 2015, Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use, Rheumatol. Int., 35, 1707, 10.1007/s00296-015-3283-4 Ebina, 2018, Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study, PLoS One, 13, 10.1371/journal.pone.0194130 Gottenberg, 2016, Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis, Arthritis Rheum., 68, 1346, 10.1002/art.39595 Harrold, 2018, Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US national observational study, J. Rheumatol., 45, 32, 10.3899/jrheum.170007 Sekiguchi, 2016, Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study, J. Rheumatol., 43, 1974, 10.3899/jrheum.160051 Bluett, 2017, Precision medicine in rheumatoid arthritis, Rheum. Dis. Clin. N. Am., 43, 377, 10.1016/j.rdc.2017.04.008 Kim, 2018, Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records, J. Korean Med. Sci., 33, e213, 10.3346/jkms.2018.33.e213